This inventor holds 6 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., Sciclone Pharmaceuticals, Inc., Tecnogen S.p.a.. Active years: 2011-2013.
Company Filing History:
3 out of 343 
2 out of 21 
1 out of 3 Years Active: 2011-2013
Title: Francesco Bistoni: Innovator in Immunotherapy
Introduction
Francesco Bistoni is a notable inventor based in Perugia, Italy. He has made significant contributions to the field of immunotherapy, particularly in the treatment of viral infections. With a total of six patents to his name, Bistoni's work has the potential to impact the medical community significantly.
Latest Patents
Among his latest patents, Bistoni has developed a method for treating humans infected with cytomegalovirus using thymosin alpha 1 as an immuno-stimulator. This method is particularly useful for preventing infections in immuno-compromised hosts undergoing bone marrow transplantation. Additionally, he has described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or ganciclovir for the preparation of a medicament aimed at preventing or treating viral diseases and inhibiting virus activation.
Career Highlights
Bistoni has worked with prominent companies in the pharmaceutical industry, including Sigma-Tau Industrie Farmaceutiche Riunite S.p.a. and Sciclone Pharmaceuticals, Inc. His experience in these organizations has allowed him to refine his expertise in immunotherapy and contribute to innovative treatments.
Collaborations
Throughout his career, Bistoni has collaborated with esteemed colleagues such as Luigina Romani and Enrico Garaci. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in medical research.
Conclusion
Francesco Bistoni's contributions to immunotherapy through his patents and collaborations highlight his role as an influential inventor in the medical field. His innovative approaches to treating viral infections demonstrate the potential for significant advancements in patient care.